Emily Bodnar
Recent Articles
Biotech Co. Still a Buy Despite Manufacturing Setbacks 07/07/2025
While it received a lower price target due to manufacturing setbacks, Jasper Therapeutics Inc. (JSPR:NASDAQ) is still a Buy, according to an H.C. Wainwright & Co. research note.
Intratubal Insemination Device Shown Effective, Safe 12/03/2024
Pregnancy rates with this "only new innovation for infertility in decades" were "impressive" in a pivotal study in women with male factor infertility, noted an H.C. Wainwright & Co. report.
Co.'s Breast Cancer Therapy Shows Encouraging Activity 12/28/2023
BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report.
Biotech Announces New Responder in Breast Cancer Trail 11/30/2023
Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar.
Encouraging Early Data For Biotech's Cancer Therapies 11/21/2023
In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24, noted H.C. Wainwright analyst Emily Bodnar.
